Log in
Enquire now
‌

US Patent 9573965 Process for the preparation of Dolutegravir

Patent 9573965 was granted and assigned to Aurobindo Pharma on February, 2017 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributors

Contents

Is a
Patent
Patent

Patent attributes

Patent Applicant
Aurobindo Pharma
Aurobindo Pharma
Current Assignee
Aurobindo Pharma
Aurobindo Pharma
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
Patent Number
9573965
Patent Inventor Names
Shankar Reddy Budidet0
Srinivasa Rao Yatcherla0
Sivakumaran Meenakshisunderam0
Subba Reddy Danda0
Srinivasachary Katuroju0
Gowrisankar Rao Kaki0
Jagan Mohan Reddy Sanapureddy0
Nageshwar Dussa0
Date of Patent
February 21, 2017
Patent Application Number
14888702
Date Filed
February 7, 2014
Patent Primary Examiner
‌
Kahsay Habte
Patent abstract

The present invention provides (R)-3-Amino-1-butanol (D)-tartarate (IIb); process for its preparation and its conversion to Dolutegravir. The present invention also provides an improved process for the preparation of Dolutegravir (I) or pharmaceutically acceptable salts wherein compound (XVI) is reacted with an optically active acid addition salt of (R)-3-amino-1-butanol (IIa).

Timeline

No Timeline data yet.

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more entities like US Patent 9573965 Process for the preparation of Dolutegravir

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.